Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, and markets ...

AI names and growth stocks have stumbled in early 2025. 2024’s big stock market winners are among the worst performers in recent weeks. AI stocks have plunged double digits amid a wave of challenging ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novo Nordisk (NVO – Research Report) and Veeva Systems (VEEV ...

While hiring activity has not yet picked up, it should do so soon, according to BioSpace Recruitment Manager Greg Clouse.

Bristol Myers Squibb is axing another 280 jobs as part of its $1.5 billion cost-cutting plan. The company is laying off 223 ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Welcome to Zymeworks fourth quarter and year-end 2024 results conference call and webcast. As a reminder, all participants are in listen-only mode and the conference is being recorded. (Operator ...

Q4 2024 Earnings Call Transcript March 5, 2025 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.

As multinational companies expand their footprint in India, leveraging the country’s technological prowess and digital ...